Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Scilex Holding Company (SCLXW)

    Price:

    0.15 USD

    ( - -0.00 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    SCLXW
    Name
    Scilex Holding Company
    Industry
    Drug Manufacturers - General
    Sector
    Healthcare
    Price
    0.148
    Market Cap
    1.267M
    Enterprise value
    138.407M
    Currency
    USD
    Ceo
    Henry H. Ji
    Full Time Employees
    115
    Ipo Date
    2021-03-05
    City
    Palo Alto
    Address
    960 San Antonio Road

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Amgen Inc.

    VALUE SCORE:

    5

    Symbol
    AMGN
    Market Cap
    207.180B
    Industry
    Drug Manufacturers - General
    Sector
    Healthcare

    2nd position

    Gilead Sciences, Inc.

    VALUE SCORE:

    8

    Symbol
    GILD
    Market Cap
    182.529B
    Industry
    Drug Manufacturers - General
    Sector
    Healthcare

    The best

    AstraZeneca PLC

    VALUE SCORE:

    8

    Symbol
    AZN
    Market Cap
    638.066B
    Industry
    Drug Manufacturers - General
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -0.245
    P/S
    1.677
    P/B
    -0.520
    Debt/Equity
    -0.382
    EV/FCF
    5.646
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    3.332
    Earnings yield
    -4.087
    Debt/assets
    0.245
    FUNDAMENTALS
    Net debt/ebidta
    -0.207
    Interest coverage
    -31.930
    Research And Developement To Revenue
    0.365
    Intangile to total assets
    0.159
    Capex to operating cash flow
    0.000
    Capex to revenue
    0.000
    Capex to depreciation
    0.000
    Return on tangible assets
    -1.620
    Debt to market cap
    1.000
    Piotroski Score
    4.000
    FUNDAMENTALS
    PEG
    0.001
    P/CF
    4.009
    P/FCF
    2.951
    RoA %
    -136.232
    RoIC %
    948.366
    Gross Profit Margin %
    68.593
    Quick Ratio
    0.043
    Current Ratio
    0.046
    Net Profit Margin %
    -931.207
    Net-Net
    -38.368
    FUNDAMENTALS PER SHARE
    FCF per share
    2.053
    Revenue per share
    3.478
    Net income per share
    -32.388
    Operating cash flow per share
    2.053
    Free cash flow per share
    2.053
    Cash per share
    0.076
    Book value per share
    -15.488
    Tangible book value per share
    -19.271
    Shareholders equity per share
    -15.248
    Interest debt per share
    6.542
    TECHNICAL
    52 weeks high
    0.170
    52 weeks low
    0.148
    Current trading session High
    0.170
    Current trading session Low
    0.114
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.367
    logo

    Country
    CN
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.099
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.629
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.588
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Instruments & Supplies
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    33.610
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -4.548
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.198
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.116
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -30.159
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -20.330
    DESCRIPTION

    Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

    NEWS